Timing clarification: The call is today, Friday, July 24, 2026, at 9:00 a.m. Central Time—not tomorrow. More importantly, HCA preannounced preliminary 2Q results and revised full-year guidance on July 14. Therefore, this is less a conventional “earnings beat/miss” setup than a call-driven assessment of the durability of earnings after a negative payer-mix reset. (investor.hcahealthcare.com)
HCA’s headline 2Q numbers were better than expected, but the market has already focused on the more important issue: commercially insured exchange members are shifting into uninsured status, while surgical volumes weakened. The July 24 call needs to establish whether this was a contained 2Q step-down or the beginning of a more material, recurring pressure on revenue yield, bad debt, and margins.
The stock has already repriced meaningfully: it closed at $376.54 on July 23, roughly 19.3% below its December 31, 2025 close, following a sharp sell-off after the July 14 preannouncement.
| Metric | Preliminary 2Q26 | 2Q25 | YoY change |
|---|---|---|---|
| Revenue | $20.23B | $18.61B | +8.7% |
| Diluted EPS | $7.62 | $6.83 | +11.6% |
| Adjusted EBITDA | $4.03B | $3.85B | +4.6% |
| Adjusted EBITDA margin | 19.9% | 20.7% | –80 bps |
| Same-facility admissions | — | — | +2.5% |
| Same-facility equivalent admissions | — | — | +2.7% |
| ER visits | — | — | +3.6% |
| Inpatient surgeries | — | — | –2.3% |
| Outpatient surgeries | — | — | –3.4% |
Preliminary revenue of $20.23 billion exceeded the approximately $19.43 billion analyst expectation reported by Reuters, while preliminary EPS of $7.62 also exceeded prevailing expectations. But the headline beat did not offset the reduction in the earnings outlook. (sahmcapital.com)
The important negative disclosure was a roughly $400 million unfavorable impact on income before taxes in 2Q from payer mix, principally more uninsured patients who lost exchange coverage. That figure included a $75 million upward revision to HCA’s prior estimate of the first-quarter exchange impact.
HCA now expects the full-year unfavorable impact from health-insurance exchanges to reach $1.0–$1.2 billion, versus its April estimate of $600–$900 million. This is the key reason the call matters: investors need visibility into whether HCA’s revised range is sufficiently conservative.
There are several layers to watch:
Uninsured migration and collections. A volume shift from exchange plans to uninsured patients is not simply a mix change; it raises the risk of lower net revenue realization and higher uncompensated care. In 1Q, HCA’s estimated cost of total uncompensated care increased to $1.25 billion from $1.06 billion a year earlier.
The grace-period issue. Management previously noted that exchange patients can receive care during a coverage grace period that ultimately may not be paid by the insurer. The call should address whether its reserve methodology and revenue recognition assumptions have now fully captured this attrition.
Surgical softness. Admissions and ER traffic were healthy, but inpatient and outpatient surgeries declined. Since surgery is typically a higher-value service category, the mix effect matters disproportionately for revenue per equivalent admission and margins.
The preliminary release also included approximately $400 million of incremental net benefit from Medicaid supplemental-payment programs, primarily tied to a Florida state-directed payment program covering October 1, 2024 through June 30, 2026.
This is a significant positive, but it also complicates the quality of the quarter:
The central question is whether the company can sustain its revised EBITDA outlook without relying on further favorable state-program approvals.
| 2026 guidance | Prior range | Revised range | Midpoint change |
|---|---|---|---|
| Revenue | $76.5B–$80.0B | $77.0B–$79.5B | Flat / narrower |
| Adjusted EBITDA | $15.55B–$16.45B | $15.40B–$16.10B | –$250M |
| Net income | $6.50B–$7.04B | $6.30B–$6.70B | –$265M |
| Diluted EPS | $29.10–$31.50 | $28.70–$30.50 | –$0.70 |
The revenue guide’s lower end increased, but the EBITDA and EPS ranges moved lower. That distinction reinforces the market’s concern: the issue is not demand alone—it is the value and collectability of that demand.
The market no longer needs confirmation that HCA delivered a decent 2Q headline beat—the company already supplied that. It needs confirmation that the earnings base has reset only once, rather than entering a period of recurring adverse payer mix, lower surgical intensity, and more difficult collections.
A constructive call would show that exchange-related losses are tracking within the revised range, surgical trends have stabilized, Medicaid-program benefits are understood, and cost actions can preserve margins. A negative call would feature additional exchange deterioration, uncertain reserve adequacy, continued procedural weakness, or commentary that makes the Medicaid benefit look like a one-time cushion masking weaker core profitability.
Near-term conclusion: expect the stock reaction to be driven by the credibility of the revised 2026 guidance, not by the already-preannounced 2Q EPS or revenue beat.